WO2023220690A1 - Transient sirolimus with fasl microgels - Google Patents
Transient sirolimus with fasl microgels Download PDFInfo
- Publication number
- WO2023220690A1 WO2023220690A1 PCT/US2023/066897 US2023066897W WO2023220690A1 WO 2023220690 A1 WO2023220690 A1 WO 2023220690A1 US 2023066897 W US2023066897 W US 2023066897W WO 2023220690 A1 WO2023220690 A1 WO 2023220690A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weeks
- sirolimus
- tapering
- administered
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/407—Liver; Hepatocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/178—Lectin superfamily, e.g. selectins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the methods comprise administering the graft cells and Fas ligand (FasL) conjugated to a hydrogel (e.g., microgel) along with a transient regimen of sirolimus.
- FasL Fas ligand
- a method of inducing immune tolerance to graft cells in a human patient in need thereof comprises administering to the human patient (i) the graft cells, (ii) a chimeric FasL protein conjugated to a hydrogel, and (iii) sirolimus, wherein the sirolimus is administered for 36 weeks or less, optionally for 24 weeks or less.
- the sirolimus is administered at an initial dose that maintains sirolimus blood trough level of about 4 ng/mL to about 16 ng/mL. In some aspects, the sirolimus is administered at an initial dose that maintains sirolimus blood trough level of about 9 ng/mL to about 16 ng/mL. In some aspects, the sirolimus is administered at an initial dose that maintains sirolimus blood trough level of about 4 ng/mL to about 15 ng/mL. In some aspects, the sirolimus is administered at an initial dose that maintains sirolimus blood trough level of about 9 ng/mL to about 15 ng/mL.
- the sirolimus is administered at an initial dose that maintains sirolimus blood trough level of about 9 ng/mL to about 13 ng/mL. In some aspects, the initial dose is administered for an initial period of about 12 weeks or less. In some aspects, the initial dose is administered for an initial period of about 1 week to about 12 weeks. In some aspects, the initial dose is administered for an initial period of about 6 weeks to about 12 weeks.
- the sirolimus is administered in a tapering regimen for a tapering period.
- the tapering regimen is administered after the initial dose for the initial period.
- the tapering regimen occurs after the initial dose for the initial period and comprises a first tapering dose administered for a first tapering period and a second tapering dose administered for a second tapering period.
- the first tapering dose maintains sirolimus blood trough levels of about 4 ng/mL to about 11 ng/mL.
- the first tapering dose maintains sirolimus blood trough levels of about 4 ng/mL to about 11 ng/mL.
- the first tapering period is about 2 weeks or less. In some aspects, the first tapering period is about 1 week to about 2 weeks.
- the second tapering dose maintains sirolimus blood trough levels of about 4 ng/mL to about 9 ng/mL. In some aspects, the second tapering dose maintains sirolimus blood trough levels of about 5 ng/mL to about 9 ng/mL. In some aspects, the second tapering period is about 2 weeks or less. In some aspects, the second tapering period is about 1 week to about 2 weeks.
- the tapering regimen further comprises a third tapering dose administered for a third tapering period.
- the third tapering dose maintains sirolimus blood trough levels of about 3 ng/mL to about 7 ng/mL.
- the third tapering period is about 2 weeks or less.
- the third tapering period is about 1 week to about 2 weeks.
- the tapering regimen further comprises a fourth tapering dose administered for a fourth tapering period.
- the fourth tapering dose maintains sirolimus blood trough levels of about 1 ng/mL to about 5 ng/mL.
- the fourth tapering period is about 2 weeks or less.
- the fourth tapering period is about 1 week to about 2 weeks.
- the tapering regimen further comprises a fifth tapering dose administered for a fifth tapering period.
- the fifth tapering dose maintains sirolimus blood trough levels of about 0 ng/mL to about 3 ng/mL.
- the fifth tapering period is about 2 weeks or less. In some aspects, the fifth tapering period is about 1 week to about 2 weeks.
- the tapering regimen comprises maintaining sirolimus blood trough levels of about 4 ng/mL to about 11 ng/mL for 2 weeks or less, maintaining sirolimus blood trough levels of about 4 ng/mL to about 9 ng/mL for 2 weeks or less, maintaining sirolimus blood trough levels of about 3 ng/mL to about 7 ng/mL for 2 weeks or less, maintaining sirolimus blood trough levels of about 1 ng/mL to about 5 ng/mL for 2 weeks or less, and/or maintaining sirolimus blood trough levels of about 0 ng/mL to about 3 ng/mL for 2 weeks or less.
- the tapering regimen comprises maintaining sirolimus blood trough levels of about 7 ng/mL to about 11 ng/mL for 2 weeks or less, maintaining sirolimus blood trough levels of about 5 ng/mL to about 9 ng/mL for 2 weeks or less, maintaining sirolimus blood trough levels of about 3 ng/mL to about 7 ng/mL for 2 weeks or less, maintaining sirolimus blood trough levels of about 1 ng/mL to about 5 ng/mL for 2 weeks or less, and/or maintaining sirolimus blood trough levels of about 0 ng/mL to about 3 ng/mL for 2 weeks or less.
- the tapering period is (i) about 12 weeks or less or (ii) about 6 weeks to about 12 weeks.
- the methods provided herein further comprise administering to the subject mesenchymal stem cells, an anti-CD20 agent, and/or an anti-CD47 agent.
- the anti-CD20 agent is rituximab.
- the graft cells are selected from peripheral blood mononuclear cells (PBMCs), bone marrow cells, hematopoietic stem cells, stem cells, stem-cell derived cells, mesenchymal stem cells, dendritic cells, dendritic cells pulsed with autoantigens, human beta cell products, pancreatic islet cells, alloislets, hepatocytes, and splenocytes.
- PBMCs peripheral blood mononuclear cells
- the graft cells are pancreatic islet cells or insulin producing stem cell- derived pancreatic islet cells.
- the graft cells are hepatocytes.
- the graft cells are stem cells or stem cell-derived cells.
- the graft cells are derived from a deceased donor.
- the graft cells are allogeneic.
- the chimeric FasL protein comprises a FasL moiety and a streptavidin or avidin moiety. In some aspects, the chimeric FasL chimeric protein further comprises a linker between the FasL moiety and the streptavidin or avidin moiety. In some aspects, the chimeric FasL protein comprises a FasL moiety and a streptavidin moiety. In some aspects, the FasL moiety is a matrix metalloproteinase resistant FasL protein. In some aspects, the chimeric FasL protein comprises the amino acid sequence of SEQ ID NO:4. In some aspects, the chimeric FasL protein is conjugated to the hydrogel via biotin.
- the hydrogel is a microgel. In some aspects, the microgel is about 125 microns to about 175 microns. In some aspects, the microgel is about 150 microns. In some aspects, the hydrogel is a polyethylene glycol (PEG) microgel. In some aspects, the hydrogel is engineered to display a biotin moiety.
- PEG polyethylene glycol
- the graft cells are not encapsulated by the hydrogel.
- a 2: 1 ratio of hydrogels: graft cells is administered.
- the immune tolerance to graft cells is induced to treat type 1 diabetes. In some aspects, at least 5,000 islet equivalents per kilogram of the human patient are administered.
- the immune tolerance to graft cells is induced to treat liver failure.
- the graft cells and the chimeric FasL protein conjugated to a hydrogel are administered to the omentum.
- the sirolimus is administered orally. In some aspects, the sirolimus is administered as an oral solution. In some aspects, the sirolimus is administered as an oral tablet. In some aspects, the sirolimus is administered once daily. In some aspects, the sirolimus administration begins on the same day or up to 5 days before the day that the graft cells and the chimeric FasL protein conjugated to a hydrogel are administered to the human subject.
- the method further comprises administering a prophylactic antiviral and an antimicrobial while the sirolimus is administered.
- the prophylactic antiviral is famciclovir.
- the antimicrobial comprises sulfamethoxazole and/or trimethoprim.
- chimeric FasL proteins conjugated to hydrogels for use in inducing immune tolerance according any method provided herein.
- FIGS 1 A and IB show local presentation of streptavidin (SA)-FasL presenting microgels for islet transplantation.
- Fig. 1 A shows synthetic biotin-PEG microgels, generated by microfluidic cross-linking, capturing, and presenting SA-FasL.
- SA-FasL- presenting microgels and islets are immobilized on the surface of the omentum of nonhuman primates (NHPs) using autologous plasma and thrombin where they induce immune acceptance.
- Fig. IB shows a schema describing donor and diabetic major histocompatibility complex (MHC) mismatched recipient NHPs and treatment protocol.
- MHC major histocompatibility complex
- SA-FasL microgels with transient sirolimus monotherapy
- microgels control microgels with transient sirolimus monotherapy
- Fig. 2B shows non-fasting blood glucose levels (mean, blue line; SEM, grey shadow, left axis) and daily total external insulin requirement (EIR) (mean, red bars; lower SEM, dark red bars, right axis) for SA- FasL microgel NHPs.
- EIR daily total external insulin requirement
- Fig. 2C shows blood glucose levels for SA-FasL-microgel NHPs after IV infusion of glucose before (Pre STZ) and after diabetes induction (Post-STZ), at 3 and 6 months post-transplantation, and post graft removal.
- FIG. 2D shows insulin (left axis) and C-peptide (right axis) levels in serum for SA-FasL microgel NHPs under fasting (F) and post-stimulation (S) before (naive) and after diabetes induction, at 3 and 6 months post-transplantation, and post-graft removal (PGR).
- Fig. 2E shows non-fasting blood glucose levels (blue line; SEM grey shadow, left axis) and daily total external insulin requirement (mean, red bars; lower SEM, dark red bars, right axis) for microgel NHPs. After restoring normoglycemia following transplantation (Tx), NHPs became hyperglycemic and required higher external insulin around 1 month post-transplantation.
- Tx normoglycemia following transplantation
- FIG. 2F shows blood glucose after IV infusion in microgel NHPs during pre-diabetic state (Pre STZ), after diabetes induction (Post-STZ), and at 1 month post-transplantation.
- Fig. 2G shows insulin (left axis) and C- 172 peptide (right axis) levels in serum for microgel NHPs under fasting (F) and poststimulation (S) before and after diabetes induction and at 1 month post-transplantation. (See Example 1.)
- Figures 3A-B show quantification of histological analyses of FoxP3 + cells over total cell counts and mean intensity in sections from microgel and SA-FasL microgel NHPs demonstrating increased frequency of Tregs in SA-FasL microgel NHPs (nested two-tailed t-test). Plots show data points for each NHP in a different color with a minimum of three representative images analyzed per NHP. (See Example 1.)
- FIG. 4A-J show that local delivery of SA-FasL-microgels does not alter peripheral blood lymphocyte populations.
- FIGS. 5A-H show that SA-FasL-microgel recipients display no significant changes in pre- to post-transplant anti-donor MHC antibodies, CD4 + and CD8 + T cell proliferative responses to donor and third-party stimulators, and IFN-y secreting cell numbers.
- FIGS 5C-F show Mixed lymphocyte reaction (mean, individual points) to CD4 + (FIG. 5C) donor and (FIG. 5D) third-party stimulators and CD8 + (FIG. 5E) donor and (FIG.
- FIGS. 5G and H show ELISpot IFN-y counts (mean, individual points) for (FIG.
- FIGS. 6A-E shows serum markers for liver and kidney function and sirolimus (“rapa”) serum levels in NHPs receiving SA-FasL or control microgels.
- BUN blood urea nitrogen
- FIG. 6B blood urea nitrogen
- FIG. 6A blood urea nitrogen
- ALT Alanine Am
- FIG. 6E shows serum sirolimus levels for individual recipients. (See Example 1.)
- Figure 7 shows a schematic of the clinical study using iTOL-101 and temporary administration of sirolimus. (See Example 2.) DETAILED DESCRIPTION OF THE INVENTION
- the term “or” is understood to be inclusive.
- the term “and/or” as used in a phrase such as “A and/or B” herein is intended to include both “A and B,” “A or B,” “A,” and “B.”
- the term “and/or” as used in a phrase such as "A, B, and/or C” is intended to encompass each of the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
- the term “sirolimus” (also known as rapamycin) refers to a macrocylic lactone compound with the chemical name 35, 67?, 7E, 97?, 1 OR, 127?, 145, 15E, 17E, 19E,215,235,267?,277?,34a5)- 9,10,12,13,14,21,22,23,24,25,26,27,32,33,34, 34a-hexadecahydro-9,27-dihydroxy-3- [(17?)-2-[(15, 37?, 47?)-4-hydroxy-3-methoxycy cl ohexyl]-l -methylethyl]- 10, 21-dimethoxy- 6,8,12,14,20,26-hexamethyl -23 ,27-epoxy-3/7-pyrido[2, 1 -c] [ 1 ,4] oxaazacyclohentriacontine-1,5, 11,28
- FasL refers to “Fas ligand,” also known as tumor necrosis factor ligand superfamily member 6, Apoptosis antigen ligand (APTL), or CD95 ligand (CD95- L).
- the sequence of human FasL protein is MQQPFNYPYPQIYWVDSSASSPWAPPGTVLPCPTSVPRRPGQRRPPPPPPPPPLPPP PPPPPLPPLPLPPLKKRGNHSTGLCLLVMFFMVLVALVGLGLGMFQLFHLQKELA ELRESTSQMHTASSLEKQIGHPSPPPEKKELRKVAHLTGKSNSRSMPLEWEDTYG IVLLSGVKYKKGGLVINETGLYFVYSKVYFRGQSCNNLPLSHKVYMRNSKYPQD LVMMEGKMMSYCTTGQMWARSSYLGAVFNLTSADHLYVNVSELSLVNFEESQ TFFGLYKL (SEQ ID NO:7).
- Amino acids 1-80 of SEQ ID NO:7 are the cytoplasmic domain of human FasL.
- Amino acids 81-102 of SEQ ID NO: 7 are the transmembrane domain of human FasL, and amino acids 103-281 of SEQ ID NO:7 are the extracellular domain of human FasL.
- a “chimeric FasL protein” refers to a protein comprising a fusion of a FasL protein or a fragment thereof to a heterologous protein (e.g., streptavidin or avidin) or fragment thereof.
- biotin hexahydro-2-oxo-lH-thieno(3,4-d)imidazole-4-pentanoic acid
- biotin-containing moieties that are able to bind to surfaces, such as cell surfaces, such as HS-biotin and EZ-LinkTM Sulfo- HS-LC-Biotin (Pierce).
- Biotin and protein-reactive forms of biotin are available commercially.
- hydrogel refers to a water swollen polymer material. These include, e.g., water-swollen polymer networks, with dimensions much larger than a cell (such as > 500pm).
- a hydrogel typically is formed when an organic polymer (natural or synthetic) is cross-linked via covalent, ionic, or hydrogen bonds to create a three- dimensional open-lattice structure which entraps water molecules to form a gel.
- Examples of materials which can be used to form a hydrogel include macromer-based materials (including PEG macromers) assembled using different cross-linking methods (such as Michael-type addition, thiol-ene, click reactions, etc.), polysaccharides (such as alginate), polyphosphazines, and polyacrylates, or block copolymers such as PluronicsTM or TetronicsTM, polyethylene oxide-polypropylene glycol block copolymers which can be cross-linked by temperature, free radical polymerization, click reactions or pH, respectively.
- macromer-based materials including PEG macromers
- cross-linking methods such as Michael-type addition, thiol-ene, click reactions, etc.
- polysaccharides such as alginate
- polyphosphazines such as alginate
- polyphosphazines such as alginate
- polyacrylates such as PluronicsTM or TetronicsTM, polyethylene oxide-polypropylene glycol block copolymers which can be cross
- microgel refers to hydrogels with smaller dimensions (such as on the order of 10s or 100s of pm).
- polypeptide polypeptide
- peptide protein
- the terms “polypeptide,” “peptide,” and “protein” are used interchangeably herein to refer to polymers of amino acids of any length.
- the polymer can be linear or branched, it can comprise modified amino acids, and it can be interrupted by non-amino acids.
- the terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component.
- polypeptides containing one or more analogs of an amino acid including, for example, unnatural amino acids, etc.
- a polypeptide, antibody, polynucleotide, vector, cell, or composition which is "isolated” is a polypeptide, antibody, polynucleotide, vector, cell, or composition which is in a form not found in nature.
- Isolated polypeptides, antibodies, polynucleotides, vectors, cell or compositions include those which have been purified to a degree that they are no longer in a form in which they are found in nature.
- an antibody, polynucleotide, vector, cell, or composition which is isolated is substantially pure.
- substantially pure refers to material which is at least 50% pure (i.e., free from contaminants), at least 90% pure, at least 95% pure, at least 98% pure, or at least 99% pure.
- Percent identity refers to the extent of identity between two sequences (e.g., amino acid sequences or nucleic acid sequences). Percent identity can be determined by aligning two sequences, introducing gaps to maximize identity between the sequences. Alignments can be generated using programs known in the art. For purposes herein, alignment of nucleotide sequences can be performed with the blastn program set at default parameters, and alignment of amino acid sequences can be performed with the blastp program set at default parameters (see National Center for Biotechnology Information (NCBI) on the worldwide web, ncbi.nlm.nih.gov).
- NCBI National Center for Biotechnology Information
- amino acids with hydrophobic side chains include alanine (A), isoleucine (I), leucine (L), methionine (M), valine (V), phenylalanine (F), tryptophan (W), and tyrosine (Y).
- Amino acids with aliphatic hydrophobic side chains include alanine (A), isoleucine (I), leucine (L), methionine (M), and valine (V).
- Amino acids with aromatic hydrophobic side chains include phenylalanine (F), tryptophan (W), and tyrosine (Y).
- amino acids with polar neutral side chains include asparagine (N), cysteine (C), glutamine (Q), serine (S), and threonine (T).
- amino acids with electrically charged side chains include aspartic acid (D), glutamic acid (E), arginine (R), histidine (H), and lysine (K).
- Amino acids with acidic electrically charged side chains include aspartic acid (D) and glutamic acid (E).
- Amino acids with basic electrically charged side chains include arginine (R), histidine (H), and lysine (K).
- the term “host cell” can be any type of cell, e.g., a primary cell, a cell in culture, or a cell from a cell line.
- the term “host cell” refers to a cell transfected with a nucleic acid molecule and the progeny or potential progeny of such a cell. Progeny of such a cell may not be identical to the parent cell transfected with the nucleic acid molecule, e.g., due to mutations or environmental influences that may occur in succeeding generations or integration of the nucleic acid molecule into the host cell genome.
- composition refers to a preparation which is in such form as to permit the biological activity of the active ingredient to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.
- the formulation can be sterile.
- administer refers to methods that may be used to enable delivery of active agents (e.g., graft cells, microgels, and/or sirolimus) to the desired site of biological action.
- active agents e.g., graft cells, microgels, and/or sirolimus
- the terms “subject” and “patient” are used interchangeably.
- the subject can be an animal.
- the subject is a mammal such as a non-human animal (e.g, cow, pig, horse, cat, dog, rat, mouse, monkey or other primate, etc.).
- the subject is a human.
- terapéuticaally effective amount refers to an amount effective to treat a disease or disorder in a subject.
- transient refers to administration that is for a limited time period and is not chronic. For example, transient administration can last no longer than 36 weeks, no longer than 30 weeks, or no longer than 24 weeks.
- a “tapering” dose or regimen refers to administration of an amount that decreases over time. Where the doses in a regimen refer to a range, “tapering” refers to ranges with decreasing upper limits, e.g., a dose regimen that achieves blood trough levels of 9-13 ng/mL for a period, then blood trough levels of 7-11 ng/mL for a period, and then blood trough levels 5-9 ng/mL is a “tapering” regimen.
- the pharmacologic and/or physiologic effect may be prophylactic, i.e., the effect completely or partially prevents a disease or symptom thereof.
- the disclosed method comprises administering a “prophylactically effective amount” of a drug (e.g., one or more antibodies or antigen-binding fragments thereof).
- a “prophylactically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired prophylactic result.
- compositions or methods provided herein can be combined with one or more of any of the other compositions and methods provided herein.
- the sirolimus is administered for 36 weeks or less. In some aspects, the sirolimus is administered for 30 weeks or less. In some aspects, the sirolimus is administered for 24 weeks or less.
- sirolimus can be administered for about 1 to about 36 weeks after graft cells are administered to a patient. In some aspects, sirolimus is administered for about 4 to about 36 weeks after graft cells are administered to a patient. In some aspects, sirolimus is administered for about 8 to about 36 weeks after graft cells are administered to a patient. In some aspects, sirolimus is administered for about 10 to about 36 weeks after graft cells are administered to a patient. In some aspects, sirolimus is administered for about 12 to about 36 weeks after graft cells are administered to a patient.
- sirolimus can be administered for about 1 to about 30 weeks after graft cells are administered to a patient. In some aspects, sirolimus is administered for about 4 to about 30 weeks after graft cells are administered to a patient. In some aspects, sirolimus is administered for about 8 to about 30 weeks after graft cells are administered to a patient. In some aspects, sirolimus is administered for about 10 to about 30 weeks after graft cells are administered to a patient. In some aspects, sirolimus is administered for about 12 to about 30 weeks after graft cells are administered to a patient.
- sirolimus can be administered for about 1 to about 24 weeks after graft cells are administered to a patient. In some aspects, sirolimus is administered for about 4 to about 24 weeks after graft cells are administered to a patient. In some aspects, sirolimus is administered for about 8 to about 24 weeks after graft cells are administered to a patient. In some aspects, sirolimus is administered for about 10 to about 24 weeks after graft cells are administered to a patient. In some aspects, sirolimus is administered for about 12 to about 24 weeks after graft cells are administered to a patient.
- the sirolimus is administered at a dose that maintains sirolimus blood trough level of about 4 ng/mL to about 16 ng/mL.
- the blood trough level of about 4 ng/mL to about 16 ng/mL is maintained for an initial period of about 12 weeks or less, e.g., about 1 week to about 12 weeks, about 2 weeks to about 12, weeks, about 3 weeks to about 12 weeks, about 4 weeks to about 12 weeks, about 5 weeks to about 12 weeks, about 6 weeks to about 12 weeks, about 7 weeks to about 12 weeks, about 8 weeks to about 12 weeks, about 9 weeks to about 12 weeks, about 10 weeks to about 12 weeks, or about 11 weeks to about 12 weeks.
- the sirolimus is administered at a dose that maintains sirolimus blood trough level of about 4 ng/mL to about 15 ng/mL.
- the blood trough level of about 4 ng/mL to about 15 ng/mL is maintained for an initial period of about 12 weeks or less, e.g., about 1 week to about 12 weeks, about 2 weeks to about 12, weeks, about 3 weeks to about 12 weeks, about 4 weeks to about 12 weeks, about 5 weeks to about 12 weeks, about 6 weeks to about 12 weeks, about 7 weeks to about 12 weeks, about 8 weeks to about 12 weeks, about 9 weeks to about 12 weeks, about 10 weeks to about 12 weeks, or about 11 weeks to about 12 weeks.
- the sirolimus is administered at a dose that maintains sirolimus blood trough level of about 9 ng/mL to about 16 ng/mL.
- the blood trough level of about 9 ng/mL to about 16 ng/mL is maintained for an initial period of about 12 weeks or less, e.g., about 1 week to about 12 weeks, about 2 weeks to about 12, weeks, about 3 weeks to about 12 weeks, about 4 weeks to about 12 weeks, about 5 weeks to about 12 weeks, about 6 weeks to about 12 weeks, about 7 weeks to about 12 weeks, about 8 weeks to about 12 weeks, about 9 weeks to about 12 weeks, about 10 weeks to about 12 weeks, or about 11 weeks to about 12 weeks.
- the sirolimus is administered at a dose that maintains sirolimus blood trough level of about 9 ng/mL to about 15 ng/mL.
- the blood trough level of about 9 ng/mL to about 15 ng/mL is maintained for an initial period of about 12 weeks or less, e.g., about 1 week to about 12 weeks, about 2 weeks to about 12, weeks, about 3 weeks to about 12 weeks, about 4 weeks to about 12 weeks, about 5 weeks to about 12 weeks, about 6 weeks to about 12 weeks, about 7 weeks to about 12 weeks, about 8 weeks to about 12 weeks, about 9 weeks to about 12 weeks, about 10 weeks to about 12 weeks, or about 11 weeks to about 12 weeks.
- the sirolimus is administered at a dose that maintains sirolimus blood trough level of about 9 ng/mL to about 13 ng/mL.
- 9 ng/mL to about 13 ng/mL is maintained for an initial period of about 12 weeks or less, e.g., about 1 week to about 12 weeks, about 2 weeks to about 12, weeks, about 3 weeks to about 12 weeks, about 4 weeks to about 12 weeks, about 5 weeks to about 12 weeks, about 6 weeks to about 12 weeks, about 7 weeks to about 12 weeks, about 8 weeks to about 12 weeks, about 9 weeks to about 12 weeks, about 10 weeks to about 12 weeks, or about 11 weeks to about 12 weeks.
- the sirolimus can be administered in a tapering regimen in which multiple doses are administered and each dose is decreased as compared to the previous dose.
- the sirolimus can be administered in a tapering regimen in which multiple doses are administered, each dose targets a blood trough range, and the upper limit of each range is decreased as compared to the previous dose.
- the sirolimus can be administered in an initial dose followed by one or more tapering doses.
- the method comprises an initial dose and at least one tapering dose (e.g., 1 to 10 tapering doses or 1 to 5 tapering doses).
- the method comprises an initial dose and at least two tapering doses (e.g., 2 to 10 tapering doses or 2 to 5 tapering doses).
- the method comprises an initial dose and at least three tapering doses (e.g., 3 to
- the initial dose can maintain sirolimus blood trough level of about 4 ng/mL to about 16 ng/mL.
- the initial dose can maintain sirolimus blood trough level of about 9 ng/mL to about 16 ng/mL.
- the initial dose can maintain sirolimus blood trough level of about 4 ng/mL to about 15 ng/mL.
- the initial dose can maintain sirolimus blood trough level of about 9 ng/mL to about 15 ng/mL.
- the initial dose can maintain sirolimus blood trough level of about 9 ng/mL to about 13 ng/mL.
- the blood trough level of is the initial dose can be maintained for an initial period of about 12 weeks or less, e.g., about 1 week to about 12 weeks, about 2 weeks to about 12, weeks, about 3 weeks to about 12 weeks, about 4 weeks to about 12 weeks, about 5 weeks to about 12 weeks, about 6 weeks to about 12 weeks, about 7 weeks to about 12 weeks, about 8 weeks to about 12 weeks, about 9 weeks to about 12 weeks, about 10 weeks to about 12 weeks, or about 11 weeks to about 12 weeks.
- the sirolimus can be administered in one or more tapering doses for one or more tapering periods.
- a first tapering dose maintains sirolimus blood trough levels of about 4 ng/mL to about 11 ng/mL, e.g., about 7 ng/mL to about 11 ng/mL.
- the first tapering period can be about 2 weeks or less, e.g., about 1 week to about 2 weeks.
- a second tapering dose maintains sirolimus blood trough levels of about 4 ng/mL to about 9 ng/mL, e.g., about 5 ng/mL to about 9 ng/mL.
- the second tapering period can be about 2 weeks or less, e.g., about 1 week to about 2 weeks.
- a third tapering dose maintains sirolimus blood trough levels of about 3 ng/mL to about 7 ng/mL.
- the third tapering period can be about 2 weeks or less, e.g., about 1 week to about 2 weeks.
- a fourth tapering dose maintains sirolimus blood trough levels of about 1 ng/mL to about 5 ng/mL.
- the fourth tapering period can be about 2 weeks or less, e.g., about 1 week to about 2 weeks.
- a fifth tapering dose maintains sirolimus blood trough levels of about 0 ng/mL to about 3 ng/mL.
- the fifth tapering period can be about 2 weeks or less, e.g., about 1 week to about 2 weeks.
- the tapering regimen comprises maintaining sirolimus blood trough levels of about 4 ng/mL to about 11 ng/mL for 2 weeks or less, maintaining sirolimus blood trough levels of about 4 ng/mL to about 9 ng/mL for 2 weeks or less, maintaining sirolimus blood trough levels of about 3 ng/mL to about 7 ng/mL for 2 weeks or less, maintaining sirolimus blood trough levels of about 1 ng/mL to about 5 ng/mL for 2 weeks or less, and/or maintaining sirolimus blood trough levels of about 0 ng/mL to about 3 ng/mL for 2 weeks or less.
- the tapering regimen comprises maintaining sirolimus blood trough levels of about 7 ng/mL to about 11 ng/mL for 2 weeks or less, maintaining sirolimus blood trough levels of about 5 ng/mL to about 9 ng/mL for 2 weeks or less, maintaining sirolimus blood trough levels of about 3 ng/mL to about 7 ng/mL for 2 weeks or less, maintaining sirolimus blood trough levels of about 1 ng/mL to about 5 ng/mL for 2 weeks or less, and/or maintaining sirolimus blood trough levels of about 0 ng/mL to about 3 ng/mL for 2 weeks or less.
- the tapering period is about 12 weeks or less.
- the tapering period can be about 1 week to about 12 weeks, about 2 weeks to about 12 weeks, about 3 weeks to about 12 weeks, about 4 weeks to about 12 weeks, about 5 weeks to about 12 weeks, about 6 weeks to about 12 weeks, about 7 weeks to about 12 weeks, about 8 weeks to about 12 weeks, about 9 weeks to about 12 weeks, about 10 weeks to about 12 weeks, or about 11 weeks to about 12 weeks.
- Sirolimus can be administered orally.
- sirolimus is administered as an oral solution.
- sirolimus is administered as an oral tablet.
- sirolimus is administered once daily.
- Administration of sirolimus can begin on the same day as the graft cells and the chimeric FasL protein conjugated to a hydrogel are administered. Alternatively, administration of sirolimus can begin prior to the day on which the graft cells and the chimeric FasL protein conjugated to a hydrogel are administered. For example, administration of sirolimus can begin about 5 days prior to the day on which the graft cells and the chimeric FasL protein conjugated to a hydrogel are administered. Administration of sirolimus can begin about 4 days prior to the day on which the graft cells and the chimeric FasL protein conjugated to a hydrogel are administered.
- Administration of sirolimus can begin about 3 days prior to the day on which the graft cells and the chimeric FasL protein conjugated to a hydrogel are administered.
- Administration of sirolimus can begin about 2 days prior to the day on which the graft cells and the chimeric FasL protein conjugated to a hydrogel are administered.
- Administration of sirolimus can begin about 1 day prior to the day on which the graft cells and the chimeric FasL protein conjugated to a hydrogel are administered FASL HYDROGELS
- FasL hydrogels e.g., microgels
- Exemplary FasL hydrogels are provided in WO 2018/165547, which is herein incorporated by reference in its entirely.
- a chimeric FasL protein can comprise a FasL moiety and a heterologous moiety.
- a FasL moiety in a chimeric FasL protein comprises a fragment of FasL (e.g., human FasL) that binds to TNFRSF6/FAS.
- TNFRSF6/FAS is a receptor that binds to FasL and transduces an apoptotic signal into cells.
- the FasL moiety comprises a fragment of FasL (e.g., human FasL) that binds to TNFRSF6B/DcR3.
- TNFRSF6B/DcR3 is a soluble decoy receptor for FasL.
- the FasL moiety comprises an apoptosis-inducing fragment of FasL.
- the FasL moiety comprises the extracellular domain of FasL.
- a FasL moiety does not comprise a transmembrane domain. In some aspects, a FasL moiety does not comprise a cytoplasmic domain. In some aspects, a FasL moiety does not comprise a transmembrane domain or a cytoplasmic domain.
- a FasL moiety in a chimeric FasL protein is matrix metalloproteinase (MMP) resistant.
- MMP matrix metalloproteinase
- the FasL moiety lacks MMP sensitive sites. See Yolcu et al, Immunity 17: 795-808 (2002).
- the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO:5 are FasL moieties that lack MMP sensitive sites.
- a chimeric FasL protein comprises a human FasL moiety comprising amino acids 131-281 of SEQ ID NO:7 or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to amino acids 131-281 of SEQ ID NO:7.
- the human FasL moiety comprising a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to amino acids 131-281 of SEQ ID NO:7 is capable of binding to TNFRSF6/FA.
- the human FasL moiety comprising a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to amino acids 131-281 of SEQ ID NO:7 is capable of inducing apoptosis in FasL- sensitive cells such as effector T cells (Teffs) and/or A20 lymphoma cells.
- FasL- sensitive cells such as effector T cells (Teffs) and/or A20 lymphoma cells.
- the human FasL moiety comprising a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to amino acids 131-281 of SEQ ID NO:7 is capable of binding to TNFRSF6/FA and is capable of inducing apoptosis in FasL-sensitive cells such as Teffs and/or A20 lymphoma cells.
- a chimeric FasL protein comprises a human FasL moiety comprising the amino acid sequence: IGHPSPPPEKKELRKVAHLTGKSNSRSMPLEWEDTYGIVLLSGVKYKKGGLVINE TGLYFVYSKVYFRGQSCNNLPLSHKVYMRNSKYPQDLVMMEGKMMSYCTTGQ MWARSSYLGAVFNLTSADHLYVNVSELSLVNFEESQTFFGLYKL (SEQ ID NO:1).
- a chimeric FasL protein comprises a rat FasL moiety comprising the amino acid sequence:
- a heterologous moiety in a chimeric FasL protein comprises a protein that is capable of binding to biotin.
- a heterologous moiety in a chimeric FasL protein comprises streptavidin or a fragment thereof.
- streptavidin or a fragment thereof refers to full-length streptavidin or a fragment of full- length streptavidin that is capable of binding to biotin.
- a heterologous moiety in a chimeric FasL protein comprises avidin or a fragment thereof.
- avidin or a fragment thereof refers to full-length avidin or a fragment of full-length avidin that is capable of binding to biotin.
- a heterologous moiety in a chimeric FasL protein comprises streptavidin or a fragment thereof or avidin or a fragment thereof.
- Fragments of streptavidin or avidin that can be in a chimeric FasL protein as provided herein include "core streptavidin” ("CSA"), a truncated version of the full-length streptavidin polypeptide which can comprise streptavidin residues 13-138, 14-138, 13- 139 or 14-139.
- CSA core streptavidin
- Other truncated forms of streptavidin and avidin that retain strong binding to biotin also can be used. See, e.g. Sano et al, J Biol Chem.
- Avidin and streptavidin are available from commercial suppliers. Moreover, the nucleic acid sequences encoding streptavidin and avidin and the streptavidin and avidin amino acid sequences are known. See, e.g., GenBank Accession Nos. X65082; X03591; NM_205320; X05343; Z21611; and Z21554.
- a chimeric FasL protein comprises a streptavidin moiety comprising the amino acid sequence: ITGTWYNQLGSTFIVTAGADGALTGTYESAVGNAESRYVLTGRYDSAPATDGSG TALGWTVAWKNNYRNAHSATTWSGQYVGGAEARINTQWLLTSGATEANAWK STLVGHDTFTKVKPSAASS (SEQ ID NO:2)
- a chimeric FasL protein comprises a streptavidin moiety comprising an amino acid sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical the amino acid sequence of SEQ ID NO:2.
- a chimeric FasL protein comprises a FasL moiety C-terminal to the heterologous moiety (e.g., the streptavidin or a fragment thereof or avidin or a fragment thereof).
- the FasL moiety located C-terminal to the heterologous moiety e.g., the streptavidin or a fragment thereof or avidin or a fragment thereof
- a chimeric FasL protein comprises a FasL moiety N-terminal to the heterologous moiety (e.g., the streptavidin or a fragment thereof or avidin or a fragment thereof).
- the FasL moiety located N-terminal to the heterologous moiety e.g., the streptavidin or a fragment thereof or avidin or a fragment thereof
- the FasL moiety and the heterologous moiety in the chimeric FasL protein are fused via an amino acid linker.
- the linker is a glycineserine linker.
- a glycine-serine linker can comprise, for example, the amino acid sequence GGGGSGGGGSG (SEQ ID NO:3).
- a chimeric FasL protein comprising a human FasL moiety comprises the amino acid sequence:
- a chimeric FasL protein comprising a rat FasL moiety comprises the amino acid sequence:
- amino acids 1-124 correspond to a streptavidin moiety
- amino acids 125-135 correspond to a glycine-serine linker
- amino acids 138-188 correspond to a FasL moiety.
- a hydrogel (e.g., a microgel) is engineered to display the chimeric FasL protein.
- a hydrogel e.g., a microgel
- a biotinylated hydrogel (e.g., microgel) is bound to a chimeric FasL protein via a non-covalent bond between biotin and streptavidin or a fragment thereof or avidin or a fragment thereof.
- a hydrogel (e.g., a microgel) comprises polyethylene glycol (PEG).
- the hydrogel e.g., a microgel
- PEG-4MAL maleimide-terminated 4-arm poly(ethylene) glycol
- Such hydrogels can be synthesized by microfluidic cross-linking. See Headen et al, Advanced Materials, 26:3003-3008 (2014).
- the PEG-4MAL platform enables stoichiometric, covalent incorporation of thiol-containing molecules, and provides improved cross-linking efficiency for formation of structurally defined hydrogels. See Phelps et al, Advanced Materials, 24: 64-70, 62 (2012).
- a hydrogel e.g., microgel
- a hydrogel is about 125 microns to about 175 microns in size. In some aspects, a hydrogel (e.g., microgel) is about 150 microns.
- Biotinylated hydrogels e.g., microgels
- Biotinylated hydrogels can be produced by reacting biotin-PEG- thiol with PEG-4MAL macromer, and generating 150 pm diameter microgels crosslinked with dithiothreitol (DTT) via microfluidics cross-linking.
- DTT dithiothreitol
- the resulting microgels can display covalently-tethered biotin capable of capturing streptavidin (SA) with high affinity.
- SA streptavidin
- the FasL in a chimeric FasL protein conjugated to a hydrogel is capable of forming FasL trimers.
- a chimeric FasL protein conjugated to a hydrogel has apoptotic activity.
- the hydrogel (e.g., microgel) comprising the chimeric FasL protein encapsulates a graft cell. In some aspects, the hydrogel (e.g., microgel) comprising the chimeric FasL protein does not encapsulate a graft cell.
- the hydrogel (e.g., microgel) comprises multiple sites for crosslinking such that additional compounds can be conjugated to the hydrogel (e.g., microgel).
- graft cell refers to a cell (or tissue or organ comprising a cell), that is administered to a subject in need thereof.
- sirolimus and a chimeric FasL protein conjugated to a hydrogel can induce specific immune tolerance to the graft cells.
- the graft cells can be cells that are derived from a donor, e.g., a deceased donor.
- the graft cells can also be stem cells or stem cell- derived cells.
- Types of graft cells include PBMCs, bone marrow cells, hematopoietic stem cells, stem cells, stem-cell derived cells, mesenchymal stem cells, dendritic cells, dendritic cells incubated with autoantigens, human beta cell products, pancreatic islet cells, alloislets, hepatocytes, and splenocytes.
- the graft cells are pancreatic islet cells or insulin producing stem cell-derived pancreatic islet cells.
- the graft cells are pancreatic islet cells.
- the graft cells are insulin producing stem cell-derived pancreatic islet cells.
- the graft cells are hepatocytes.
- Types of graft cells also include islet cells (e.g., pancreatic islet cells), splenocytes, PBMCs, bone marrow cells, mesenchymal stem cells, hematopoietic stem cells, stem cells, induced pluripotent stem cells, human beta cell products, hepatocytes, dendritic cells, macrophages, endothelial cells, cardiac myocytes, and vascular cells, and immune cells, including T cells, etc.
- the graft cell can be administered as a preparation of isolated cells or as part of a tissue or organ.
- the graft cell is allogeneic. In some aspects, the grant cell is xenogenic. In some aspects, the graft cell is from a human. In some aspects, the graft cell is from a non-human primate, a dog, a cat, a cow, a sheep, a horse, a rabbit, a mouse, or a rat.
- the graft cells for use as provided herein can be graft cells that were obtained from a deceased donor.
- the graft cell is autologous or autogenic (from the subject being treated).
- an autologous graft cell can be derived from autologous tissue by induced pluripotency and differentiation of the induced pluripotent cells to the desired autologous graft cell.
- cells from the subject are used to induce immune tolerance to self that has been interrupted in autoimmune disease.
- the graft cell is encapsulated by the hydrogel (e.g., microgel) comprising the chimeric FasL protein. In some aspects, the graft cell is not encapsulated by the hydrogel (e.g., microgel) comprising the chimeric FasL protein.
- pancreatic islet cells can be administered, along with a tapering and/or transient sirolimus regimen and a chimeric FasL protein conjugated to a hydrogel, to treat diabetes.
- hepatocytes can be administered, along with a sirolimus chimeric FasL protein conjugated to a hydrogel, to treat acute liver failure or liver-based metabolic disorders.
- the methods are for preventing or reducing the risks of rejection of cellular or tissue grafts and/or for the treatment of Type I diabetes.
- the methods can comprise administering the graft cells, a chimeric FasL protein conjugated to a hydrogel, and sirolimus.
- the hydrogel (e.g., microgel) comprising the chimeric FasL protein and the graft cell are administered simultaneously.
- the graft cell is not encapsulated by the hydrogel (e.g., microgel).
- the graft cell and the hydrogel can be administered in the same pharmaceutical composition or can be administered in separate pharmaceutical compositions.
- the graft cell is encapsulated by the hydrogel (e.g., microgel).
- the hydrogel e.g., microgel
- the hydrogel and graft cells are administered in a ratio of about 2 hydrogels (e.g., microgels): 1 cell.
- the methods of inducing immune tolerance provided herein are for the treatment of Type I diabetes in a human patient. Accordingly, in some aspects, at least 3,000 islet equivalents per kilogram of the patient are administered. In some aspects, at least 5,000 islet equivalents per kilogram of the patient are administered. In some aspects, at least 10,000 islet equivalents per kilogram of the patient are administered. In some aspects, at least 11,000 islet equivalents per kilogram of the patient are administered. In some aspects, about 3,000 to about 20,000 islet equivalents per kilogram of the patient are administered. In some aspects, about 5,000 to about 20,000 islet equivalents per kilogram of the patient are administered. In some aspects, about 10,000 to about 20,000 islet equivalents per kilogram of the patient are administered. In some aspects, about 11,000 to about 20,000 islet equivalents per kilogram of the patient are administered.
- the hydrogel and graft cells are administered in a ratio of about 2 hydrogels (e.g., microgels): 1 alloislet.
- the methods of inducing immune tolerance provided herein are for the treatment of liver failure, e.g., by administering a therapeutically effective amount of hepatocytes, a chimeric FasL protein conjugated to a hydrogel, and transient sirolimus.
- the graft cells and the chimeric FasL protein conjugated to a hydrogel are administered to the omentum.
- the hydrogels e.g., microgels
- graft cells e.g., graft cells
- sirolimus are administered or for administration in combination with mesenchymal stem cells (MSCs), an anti-CD20 agent (such as rituximab), or an anti-CD46 agent.
- MSCs mesenchymal stem cells
- an anti-CD20 agent such as rituximab
- an anti-CD46 agent such as rituximab
- the sirolimus is administered in combination with a prophylactic antiviral (e.g., famciclovir). In some aspects, the sirolimus is administered in combination with an antimicrobial (e.g., sulfamethoxazole and/or trimethoprim). In some aspects, the sirolimus is administered in combination with a prophylactic antiviral (e.g., famciclovir) and an antimicrobial (e.g., sulfamethoxazole and/or trimethoprim).
- a prophylactic antiviral e.g., famciclovir
- an antimicrobial e.g., sulfamethoxazole and/or trimethoprim
- administration “in combination” with can refer to simultaneous administration or sequential administration.
- simultaneous administration can comprise administration in the same pharmaceutical composition or in separate pharmaceutical compositions.
- Biotinylated PEG microgels (150 pm diameter) were synthesized by microfluidic cross-linking and functionalized with SA-FasL as previously described (Headon, DM, et al., Nat. Mater. 17'. 732-739 (2016)).
- SA-FasL four diabetic non-human primates (NHP) (FIG. IB; Tables 1 and 2) underwent transplantation of allogeneic islets (14,800 to 18,700 islet equivalents (IEQ)/kg) mixed with SA-FasL-presenting microgels (150,000 to 200,000 microgels delivering 0.2 mg of SA-FasL) on the omental surface.
- NHS non-human primates
- FIG. 2B presents non-fasting blood glucose levels (left axis) and administered external total daily insulin requirement (EIR; right axis) averaged across all SA-FasL- presenting microgel recipients.
- EIR external total daily insulin requirement
- FIG. 2B presents non-fasting blood glucose levels (left axis) and administered external total daily insulin requirement (EIR; right axis) averaged across all SA-FasL- presenting microgel recipients.
- EIR external total daily insulin requirement
- Three SA-FasL microgel NHPs required exogenous insulin post-transplantation, but only 10-20% of the pre-transplant dose to maintain postprandial blood glucose levels below 250 mg/dL.
- IVGTT intravenous glucose tolerance tests
- FIG. 2E presents random non-fasting blood glucose levels (left axis) and total daily EIR 227 (right axis) averaged across all recipients receiving control microgels (referred to herein as simply “microgel”).
- microgel NHPs had average non-fasting blood glucose levels around 400 mg/dL while requiring 15-20 units of exogenous insulin per day. After transplantation, microgel NHPs experienced uneventful recovery, and average blood glucose levels returned to the normal range. However, around day 30 post-transplantation, blood glucose levels and required external insulin dose increased and remained elevated at levels comparable to the diabetic pretransplantation state, indicating graft rejection (blood glucose levels: post-transplant vs.
- FIG. 4 presents longitudinal profiles for immune cell populations.
- Multiplexed immunobead assays showed no significant differences between pre- and post-transplantation levels of pro-inflammatory and anti-inflammatory cytokines and chemokines in the serum of SA-FasL microgel and microgel NHPs.
- iTOL-101 is made up of two components: 1) the iTOL-100 drug product (SA- FasL microgel) and 2) the allogeneic deceased donor pancreatic islets drug product.
- Alloislet dose varies from subject to subject but at least 5,000 islet equivalents (IEQ)/kg of functional islets are delivered for each study subject. Assessment of the total IEQ and minimal dose required for transplant (5,000 lEQ/kg) are determined in accordance with the standard operating procedures (SOPs) used in the National Institutes of Health (NIH) CIT Phase 3 Clinical Trial (ClinicalTrials.gov Identifier: NCT00434811).
- SOPs standard operating procedures
- iTOL-100 dose of 0.7 mg SA-FasL in approx. 11 mL of Dulbecco's phosphate-buffered saline is mixed with 350,000 islets (5,000 lEQ/kg) to produce the final delivered dose.
- the volume of iTOL-100 is adjusted vokvol with any increases in total amount of pancreatic islets to be implanted.
- T1D Type 1 Diabetes
- hypoglycemia unawareness as measured by a Clarke score >4 and at least one of the following criteria: o At least 2 episodes of severe hypoglycemia as defined by American Diabetes Association (ADA) criteria in the 12 months prior to enrollment, despite involvement in intense diabetes management; o HbAlc >8.0 and glycemic variability >36% (cv); o HbAlc >7.0 and >8% time below range (blood glucose levels ⁇ 70 mg/dL)
- iTOL-101 The 2 components of iTOL-101 are mixed together at the clinical site and administered via laparoscopic surgery using a 12-French gastrostomy catheter to deliver iTOL-101 to the surface of the greater omentum under pre-transplant sedation and general anesthesia per standard of care.
- Human recombinant thrombin is added as needed to cover the graft surface with the volume added approximately equal to the volume of the graft implanted to promote adhesion of the islets to the surface of the greater omentum and avoid cell pelleting.
- an omental pouch (omental flap) is created by folding the omentum over the iTOL-101 implant.
- the entire procedure, including preparation and delivery of iTOL-101 and formation of omental flap, can be completed in less than 30 minutes.
- Sirolimus mTOR inhibitor
- study subjects are given sirolimus the first 12 weeks adjusted to maintain blood trough levels of 9-13 ng/mL, followed by a 12-week tapering regimen, with a decrease every 2 weeks (+/- 7 days) based on blood trough levels.
- Per sirolimus labeling, prophylactic antiviral (famciclovir), and antimicrobial agents are also be given to subjects for 24 weeks.
- the sirolimus regimen is as follows:
- Laparoscopic port site assessments e.g., bleeding, erythema, pain, tenderness, induration, discharge) post-implantation and at subsequent visits;
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2023268552A AU2023268552A1 (en) | 2022-05-12 | 2023-05-11 | Transient sirolimus with fasl microgels |
| JP2024567558A JP2025516714A (ja) | 2022-05-12 | 2023-05-11 | Faslミクロゲルを用いた一過性シロリムス |
| EP23804516.5A EP4522236A4 (en) | 2022-05-12 | 2023-05-11 | TRANSIENT SIROLIMUS WITH FASL MICROGELS |
| US18/865,252 US20250312321A1 (en) | 2022-05-12 | 2023-05-11 | Transient sirolimus with fasl microgels |
| CA3257338A CA3257338A1 (en) | 2022-05-12 | 2023-05-11 | TRANSIENT SIROLIMUS WITH FASL MICROGELS |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263364607P | 2022-05-12 | 2022-05-12 | |
| US63/364,607 | 2022-05-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023220690A1 true WO2023220690A1 (en) | 2023-11-16 |
Family
ID=88731172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2023/066897 Ceased WO2023220690A1 (en) | 2022-05-12 | 2023-05-11 | Transient sirolimus with fasl microgels |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250312321A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4522236A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025516714A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023268552A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3257338A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023220690A1 (cg-RX-API-DMAC7.html) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200046780A1 (en) * | 2017-03-10 | 2020-02-13 | University Of Louisville Research Foundation, Inc. | Fasl-engineered biomaterials with immunomodulatory function |
| US20210105999A1 (en) * | 2018-03-29 | 2021-04-15 | Bruno Reichart | Compositions for prolonging the survival after orthotopic and heterotopic xenogeneic heart, kidney, lung or liver transplantations |
-
2023
- 2023-05-11 AU AU2023268552A patent/AU2023268552A1/en active Pending
- 2023-05-11 JP JP2024567558A patent/JP2025516714A/ja active Pending
- 2023-05-11 WO PCT/US2023/066897 patent/WO2023220690A1/en not_active Ceased
- 2023-05-11 CA CA3257338A patent/CA3257338A1/en active Pending
- 2023-05-11 US US18/865,252 patent/US20250312321A1/en active Pending
- 2023-05-11 EP EP23804516.5A patent/EP4522236A4/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200046780A1 (en) * | 2017-03-10 | 2020-02-13 | University Of Louisville Research Foundation, Inc. | Fasl-engineered biomaterials with immunomodulatory function |
| US20210105999A1 (en) * | 2018-03-29 | 2021-04-15 | Bruno Reichart | Compositions for prolonging the survival after orthotopic and heterotopic xenogeneic heart, kidney, lung or liver transplantations |
Non-Patent Citations (1)
| Title |
|---|
| See also references of EP4522236A4 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4522236A1 (en) | 2025-03-19 |
| CA3257338A1 (en) | 2023-11-16 |
| EP4522236A4 (en) | 2025-12-31 |
| AU2023268552A1 (en) | 2024-11-21 |
| JP2025516714A (ja) | 2025-05-30 |
| US20250312321A1 (en) | 2025-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI824258B (zh) | 包含il-2蛋白及cd80蛋白之融合蛋白及其用途 | |
| US9125893B2 (en) | Highly concentrated anti-CD40 antibody pharmaceutical preparation | |
| DE60225914T2 (de) | Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4-mutationsmolekülen | |
| US8728747B2 (en) | Alteration of cell membrane for new functions | |
| JP2015038084A (ja) | 自己免疫疾患の治療および/または予防のための薬剤、ならびに制御性t細胞形成のための薬剤 | |
| EP3065765B1 (en) | Use of il-22 dimers in manufacture of medicaments for treating pancreatitis | |
| JP2007534698A (ja) | 持続放出製剤 | |
| WO2005072045A2 (en) | The combined use of glp-1 agonists and gastrin for regulating blood glucose levels | |
| RS64754B1 (sr) | Fasl-izrađeni biomaterijali sa imunomodularnom funkcijom | |
| EP1455766B1 (en) | Thymosin alpha 1 peptide/polymer conjugates | |
| EP2566500B1 (en) | Ccl1 for use in therapy | |
| EP2267030A1 (en) | Devices, compositions and methods for the protection and repair of cells and tissues | |
| WO2015148831A1 (en) | Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide | |
| US20250312321A1 (en) | Transient sirolimus with fasl microgels | |
| US9717777B2 (en) | Use of CCL1 in therapy | |
| KR20190135516A (ko) | 자가 면역 질병 및 당뇨병의 치료를 위한 바이러스 벡터 및 그의 제조방법 및 응용 | |
| WO2025255498A1 (en) | Biocompatible polymer compositions and methods of use | |
| WO2023183953A1 (en) | Delivery of dissociated islets cells within microporous annealed particle scaffold to treat type 1 diabetes | |
| KR20090118629A (ko) | 암 또는 자가 면역 질환 치료를 위한peg-trail/히알루론산 나노복합체 수화젤의서방형 약물 방출 시스템 | |
| Giraldo | Pegylation and bioactive modification of pancreatic islet surfaces to enhance graft survival in cell therapy for type I diabetes | |
| Woodward | Targeting Fas pathway as an effective means of inducing tolerance to pancreatic islets. | |
| Kim | Characterization of pattern recognition receptor responses against materials for cell encapsulation | |
| HK40037000A (en) | Glp-2 analogs and peptibodies for administration before during, or after surgery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23804516 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: AU2023268552 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2024567558 Country of ref document: JP |
|
| ENP | Entry into the national phase |
Ref document number: 2023268552 Country of ref document: AU Date of ref document: 20230511 Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2023804516 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2023804516 Country of ref document: EP Effective date: 20241212 |
|
| WWP | Wipo information: published in national office |
Ref document number: 18865252 Country of ref document: US |